Advisors Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Advisors Asset Management's MLTX Position: Q3 2026 in Review
Advisors Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 57% in Q3 2026, selling an estimated $37.2K and leaving 1,716 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1385.
Advisors Asset Management first reported a position in MLTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $189K in Q2 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Advisors Asset Management held 1,716 shares of MoonLake Immunotherapeutics worth $20.1K as of Q3 2026.
- Advisors Asset Management sold 2,275 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $37.2K.
- MoonLake Immunotherapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q3 2026, its #1385 holding.
- Advisors Asset Management first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 8 quarters since.
- Advisors Asset Management's MoonLake Immunotherapeutics position peaked at $189K in Q2 2025.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.